Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Consensus Price Target from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given a consensus recommendation of “Buy” by the seven ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $15.80.

Several research firms have issued reports on ZURA. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after acquiring an additional 2,611,532 shares during the last quarter. Braidwell LP acquired a new position in Zura Bio in the 3rd quarter worth about $10,040,000. Sphera Funds Management LTD. purchased a new stake in shares of Zura Bio during the 3rd quarter worth about $2,999,000. Millennium Management LLC lifted its holdings in shares of Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after buying an additional 657,420 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after buying an additional 377,545 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Stock Performance

Shares of NASDAQ ZURA opened at $1.23 on Monday. The stock’s fifty day simple moving average is $1.65 and its 200 day simple moving average is $2.95. Zura Bio has a 52-week low of $1.10 and a 52-week high of $6.35.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.